The content on this site is intended for healthcare professionals only
Prof Arthur Sun Myint speaks to ecancer as part of ASCO GI 2022 about the OPERA study which looked at the role of radiation dose escalation using Contact X-ray brachytherapy (CXB) in order to avoid surgery in rectal cancer.
He explains that patients were randomised between two arms: Arm A (standard of care with EBRT boost) and Arm B (experimental with CXB boost).
Prof Myint reports that surgical treatment is feasible and failures can still be salvaged with chances of survival not compromised.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Lung cancer highlights
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
The parotid gland; an unusual site of colorectal cancer metastasis
ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery
